Leerink Partnrs also issued estimates for Turnstone Biologics’ Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.69) EPS ...

Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Free Report) – Research analysts at Leerink Partnrs increased their FY2025 earnings per share estimates for shares of Tenaya Therapeutics in a note ...

Still, the biopharma industry may have “more wiggle room” on the issue than first expected, analysts at Leerink Partners wrote in a Friday note responding to AgencyIQ’s concerns. Notably ...

In a report released on April 1, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The company’s shares closed yesterday at $19.29.

“This is yet another unfortunate development for a story that cannot seem to catch a break,” Leerink wrote on Wednesday, adding that the weight of a 16-year-old patient likely means that he ...

J.P. Morgan analyst Anne E. Samuel reiterated the Neutral rating on Premier, Inc. (NASDAQ:PINC) on Tuesday, with a price forecast of $19. The analyst notes that Premier’s stable business is ...

It was previously corrected to change the brokerage's name to Leerink Partners, not Jefferies, in paragraph 4) Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's ...

Leerink lowered the firm’s price target on AirSculpt Technologies (AIRS) to $2.50 from $6.50 and keeps a Market Perform rating on the shares. Q4 results featured a continuation of challenges ...

Leerink Partners analysts said in a note to investors that Lundbeck determined subcutaneous delivery “was not demonstrating the desired treatment effect.” The analysts have questions about the ...

The last upgrade for Compass Therapeutics Inc happened on April 2, 2025 when Leerink Partners raised their price target to $6. Leerink Partners previously had a market perform for Compass ...

Leerink Partners analyst David Risinger wrote that the big questions remaining are who will replace Marks and whether they will be able to stand up to the Trump administration if needed. In addition, ...